



# SUVEN LIFE SCIENCES LTD

Off:SDE Serene Chambers,6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

## STATEMENT OF UN AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER 31, 2021.

		Rs. In Lakhs					
PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 Months period ended		For the year ended
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	<b>Income</b>						
	Revenue from operations	443.29	118.41	151.30	762.31	1,192.12	1,347.83
	Other Income	14.09	50.28	162.41	519.89	643.06	775.37
	<b>Total income</b>	<b>457.38</b>	<b>168.69</b>	<b>313.71</b>	<b>1,282.20</b>	<b>1,835.18</b>	<b>2,123.20</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	410.44	420.55	379.91	1,240.73	1,206.73	1,528.50
	d) Finance costs	12.96	14.99	14.19	43.24	57.36	81.54
	e) Depreciation and amortisation expense	122.22	103.43	114.11	329.08	328.06	434.62
	f) Manufacturing Expenses	-	-	-	-	-	-
	g) R & D Expenses	564.39	602.49	730.42	2,050.89	1,927.08	2,517.04
	h) Other Expenses	169.29	125.51	80.47	387.75	265.23	356.99
	<b>Total expenses</b>	<b>1,279.30</b>	<b>1,266.97</b>	<b>1,319.10</b>	<b>4,051.69</b>	<b>3,784.46</b>	<b>4,918.69</b>
3	Profit before exceptional items & Tax (1-2)	(821.92)	(1,098.28)	(1,005.39)	(2,769.49)	(1,949.28)	(2,795.49)
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	(821.92)	(1,098.28)	(1,005.39)	(2,769.49)	(1,949.28)	(2,795.49)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	(190.68)	-	(536.86)	(532.28)
7	Net Profit/ (Loss) for the period/year(5-6)	(821.92)	(1,098.28)	(814.71)	(2,769.49)	(1,412.42)	(2,263.21)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(11.78)	(11.79)	(11.36)	(35.36)	(34.06)	(47.15)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	3.97	-	11.90	16.48
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(11.78)</b>	<b>(11.79)</b>	<b>(7.39)</b>	<b>(35.36)</b>	<b>(22.16)</b>	<b>(30.67)</b>
9	Total Comprehensive Income for the period (7+8)	(833.70)	(1,110.07)	(822.10)	(2,804.85)	(1,434.58)	(2,293.88)
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity						35,200.64
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(0.65)	(0.86)	(0.64)	(2.18)	(1.11)	(1.78)
	b) Diluted	(0.65)	(0.86)	(0.64)	(2.18)	(1.11)	(1.78)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



PART - I		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 Months period ended		For the year ended
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	443.29	118.41	151.30	762.31	1,192.12	1,347.83
	Other Income	14.09	50.28	162.41	519.89	643.06	775.37
	Total income	457.38	168.69	313.71	1,282.20	1,835.18	2,123.20
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	506.01	514.35	450.14	1,525.89	1,435.70	1,852.75
	d) Finance costs	12.96	14.99	14.19	43.24	57.36	81.54
	e) Depreciation and amortisation expense	122.23	103.43	114.11	329.09	328.06	434.62
	f) Manufacturing Expenses	-	-	-	-	-	-
	g) R & D Expenses	3,007.31	2,231.46	2,273.74	9,091.00	5,307.15	7,102.73
	h) Other Expenses	177.90	134.28	91.50	412.68	297.65	398.96
	Total expenses	3,826.41	2,998.51	2,943.68	11,401.90	7,425.92	9,870.60
3	Profit before exceptional items , Tax (1-2)	(3,369.03)	(2,829.82)	(2,629.97)	(10,119.70)	(5,590.74)	(7,747.40)
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	(3,369.03)	(2,829.82)	(2,629.97)	(10,119.70)	(5,590.74)	(7,747.40)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	(190.68)	-	(536.86)	(532.28)
7	Net Profit/ (Loss) for the period/year(5-6)	(3,369.03)	(2,829.82)	(2,439.29)	(10,119.70)	(5,053.88)	(7,215.12)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(11.78)	(11.79)	(11.36)	(35.36)	(34.06)	(47.15)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	3.97	-	11.90	16.48
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(11.78)	(11.79)	(7.39)	(35.36)	(22.16)	(30.67)
9	Total Comprehensive Income for the period ( 7+ 8)	(3,380.81)	(2,841.61)	(2,446.68)	(10,155.06)	(5,076.04)	(7,245.79)
10	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity	-	-	-	-	-	5,835.74
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(2.65)	(2.22)	(1.92)	(7.95)	(3.97)	(5.67)
	b) Diluted	(2.65)	(2.22)	(1.92)	(7.95)	(3.97)	(5.67)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



**NOTES:-**

- 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 31, 2022. The results for the quarter ended December 31, 2021 has been reviewed by our statutory auditors
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences , Inc
- 4) The COVID-19 has marginal impact on the business and research operations in India. Further, we are foreseeing certain delays in enrollment of ongoing phase 2 clinical studies conducted in our subsidiary, Suven Neurosciences, Inc USA.
- 5) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 6) During the year ended 31-03-2021 with the approval of members in EGM held on 20th March'2021, the board has issued 1,81,00,000 share warrants to promoter group on a preferential basis @ ₹ 81.57 per warrant and received amounting to ₹ 7,764.17 lakhs till 31.12.2021.
- 7) The other income includes Insurance claim amount received aggregating to Rs.371.58 lakhs.
- 8) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad  
Date : January 31, 2022



For SUVEN LIFE SCIENCES LTD

  
**VENKAT JASTI**  
Chairman & CEO  
DIN: 00278028